Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer
Year: 2019
Type: article
Abstract: (Cell Reports 22, 2236–2245; February 27, 2018) In the originally published version of this article, the crystal violet images on the third panel of Figure 2L were inadvertently presented again on the top panel of Figure 4B (a). This mistake happened during the assembly of figures and has now been corrected online. The authors regret this error. Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerPawar et al.Cell ReportsFebruary 27, 2018In BriefResistance to targeted therapies is a major problem. Pawar et al. investigate the potential mechanisms of acquired resistance to BET inhibitors in prostate cancer and identify actionable targets to overcome the resistance. This study highlights the therapeutic limitation of BET inhibitors as a monotherapy and suggests potential combination therapies in treating prostate cancer. Full-Text PDF Open Access
Source: Cell Reports
Authors: Aishwarya Pawar, Paradesi Naidu Gollavilli, Shaomeng Wang, Irfan A. Asangani
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,200
OpenAlex ID: W4243427893